ストックスクリーナーアプリを入手
120.87
0.02%
0.03
前日終値:
$120.84
開ける：
$120.37
24時間の取引高:
6.26M
Relative Volume:
0.54
時価総額：
$298.84B
収益：
$64.93B
当期純損益:
$18.26B
株価収益率:
16.61
EPS:
7.2751
ネットキャッシュフロー:
$12.36B
1週間 パフォーマンス:
+1.63%
1か月 パフォーマンス:
-0.44%
6か月 パフォーマンス:
+35.04%
1年 パフォーマンス:
+39.57%
1日の値動き範囲:
$119.22
$121.65
1週間の範囲:
$117.22
$122.19
52週間の値動き範囲:
$73.31
$125.14
Merck Co Inc Stock (MRK) Company Profile
Compare MRK vs LLY, JNJ, ABBV, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-02-13 | アップグレード | Deutsche Bank | Hold → Buy |
| 2026-01-08 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-10-13 | 再開されました | Citigroup | Neutral |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-02-18 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-02-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-01-08 | ダウングレード | Truist | Buy → Hold |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-12-04 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-11 | ダウングレード | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-03-11 | ダウングレード | Societe Generale | Hold → Sell |
| 2024-01-04 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-27 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | アップグレード | UBS | Neutral → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Hold |
| 2023-04-13 | アップグレード | Citigroup | Neutral → Buy |
| 2023-03-28 | ダウングレード | Societe Generale | Buy → Hold |
| 2023-03-13 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 開始されました | Jefferies | Buy |
| 2023-02-22 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-10-10 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-14 | アップグレード | Berenberg | Hold → Buy |
| 2022-07-06 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 再開されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-16 | 開始されました | Daiwa Securities | Neutral |
| 2021-12-13 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-12-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-29 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-01 | アップグレード | Argus | Hold → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-20 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-08-03 | アップグレード | Goldman | Neutral → Buy |
| 2020-06-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-16 | 開始されました | SVB Leerink | Outperform |
| 2019-07-03 | 開始されました | Mizuho | Buy |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-05-13 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 繰り返されました | Citigroup | Buy |
| 2018-10-09 | 再開されました | Guggenheim | Buy |
| 2018-04-23 | アップグレード | Goldman | Neutral → Buy |
| 2018-04-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-03-12 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-07 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2018-01-16 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Merck Co Inc (MRK) 最新ニュース
Merck & Co., Inc. $MRK Stock Position Trimmed by Florida Trust Wealth Management Co - marketbeat.com
Perpetual Ltd Purchases 9,261 Shares of Merck & Co., Inc. $MRK - MarketBeat
SS&H Financial Advisors Inc. Acquires 12,200 Shares of Merck & Co., Inc. $MRK - marketbeat.com
SteelPeak Wealth LLC Grows Stock Holdings in Merck & Co., Inc. $MRK - marketbeat.com
Merck & Co., Inc. $MRK Shares Purchased by Quintet Private Bank Europe S.A. - MarketBeat
Leerink raises Merck & Co. Inc. (MRK) price target, sees upside from cancer drug - MSN
Merck & Co., Inc. stock: Steady performer amid healthcare shifts - AD HOC NEWS
Erste Group Initiates Merck & Co(MRK.US) With Hold Rating - Moomoo
West Branch Capital LLC Sells 15,875 Shares of Merck & Co., Inc. $MRK - marketbeat.com
Merck & Co., Inc. stock: Strong margins amid shifting pharma winds - ad-hoc-news.de
Eldred Rock Partners LLC Has $11.31 Million Stake in Merck & Co., Inc. $MRK - marketbeat.com
10,200 Shares in Merck & Co., Inc. $MRK Purchased by FNY Investment Advisers LLC - marketbeat.com
16,300 Shares in Merck & Co., Inc. $MRK Purchased by Dorato Capital Management - marketbeat.com
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Grows Stock Holdings in Merck & Co., Inc. $MRK - marketbeat.com
Merck & Co., Inc. $MRK Shares Bought by Aberdeen Group plc - marketbeat.com
Merck & Co., Inc. stock: A cornerstone of pharmaceutical innovation and dividend reliability for lon - AD HOC NEWS
FinancialContentMerck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer - markets.financialcontent.com
Merck Just Made a Big Bet on a New Cancer Growth Engine - Investing.com
Merck initiates Phase 2b/3 trial for treatment of age-related macular degeneration - ROI-NJ
Merck Announces Initiation of Pivotal Phase 2B/3 Trial Evaluating Mk-8748 for Treatment of Neovascular Age-Related Macular Degeneration - MarketScreener
Merck & Co Inc (MEX:MRK) Stock Price, Trades & News - gurufocus.com
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investiga - PharmiWeb.com
Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study - Insider Monkey
Merck's (MRK) Keytruda Gains Fast Track Status in Colorectal Can - gurufocus.com
Chongqing Zhifei Biological Products adjusts cooperation agreement with Merck & Co - MarketScreener
Merck wins EU nod for Keytruda combo in ovarian cancer (MRK) - Seeking Alpha
Merck (MRK) Gains EU Approval for Keytruda Regimen in Ovarian Ca - GuruFocus
Merck (MRK) Advances MK-8748 Trial for Eye Disease Treatment - gurufocus.com
Merck Says EU Approves Keytruda Combination Regimen for Platinum-Resistant Ovarian Cancer - MarketScreener
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration - Business Wire
Tema Etfs LLC Raises Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Compagnie Lombard Odier SCmA - marketbeat.com
Bank Pictet & Cie Europe AG Lowers Stake in Merck & Co., Inc. $MRK - marketbeat.com
Merck & Co., Inc. $MRK Shares Sold by Banque Pictet & Cie SA - marketbeat.com
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9 - Insider Monkey
Startup Infinimmune sees close to $1 billion, validation in big Merck drug dealSan Francisco Business Times - The Business Journals
Merck (NYSE: MRK) director receives new cash-settled phantom stock grant - Stock Titan
Merck (MRK) director Glocer granted 405 phantom stock units, holds 5,100 shares - Stock Titan
Merck (NYSE: MRK) director granted new phantom stock units - Stock Titan
Merck & Co deal worth up to $838 million to Infinimmune - The Pharma Letter
What's Going On With Merck Stock Wednesday?Merck & Co (NYSE:MRK) - Benzinga
Vaughan Nelson Investment Management L.P. Sells 11,515 Shares of Merck & Co., Inc. $MRK - marketbeat.com
Merck & Co., Inc. $MRK Shares Sold by Highline Wealth Partners LLC - marketbeat.com
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30 - Business Wire
Nisa Investment Advisors LLC Increases Holdings in Merck & Co., Inc. $MRK - marketbeat.com
Merck & Co., Inc. $MRK Shares Bought by Moody Lynn & Lieberson LLC - marketbeat.com
Shrier Wealth Management LLC Buys New Position in Merck & Co., Inc. $MRK - marketbeat.com
Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More - Yahoo Finance
Econ Financial Services Corp Sells 8,757 Shares of Merck & Co., Inc. $MRK - marketbeat.com
Allspring Global Investments Holdings LLC Has $96.05 Million Holdings in Merck & Co., Inc. $MRK - marketbeat.com
Merck (MRK) Gains But Lags Market: What You Should Know - Yahoo Finance
Merck Co Inc (MRK) 財務データ
収益
当期純利益
現金流量
EPS
0.68%
1.37%
大文字化:
|
ボリューム (24 時間):